PMID: 6084435Jan 1, 1984Paper

Procainamide: clinical pharmacology and efficacy against ventricular arrhythmias

Annals of the New York Academy of Sciences
E G Giardina


Procainamide (PA) has been a mainstay of treatment against acute and chronic supraventricular and ventricular arrhythmias for more than 30 years. PA's clinical pharmacology has been studied extensively and its bioavailability (75-95%); volume of distribution (1.5-2.5 liters per kg), plasma protein-binding (15-25%), half-time for elimination (3-7 hours), and metabolism are known. PA's efficacy against acute ventricular arrhythmias and chronic stable VPDs is associated with plasma drug concentrations of 4 to 10 micrograms per ml; but much higher plasma concentrations may be required against sustained ventricular arrhythmias. From 30 to 60% of a PA dose is excreted as the metabolite, N-acetylprocainamide (NAPA), and PA's metabolism is determined genetically (fast or slow acetylation phenotype). Studies in patients with VPDs indicate that NAPA is also antiarrhythmic, although the contribution of NAPA to the antiarrhythmic effect after PA is not known. Studies in patients with the systemic lupus-like syndrome from PA show that NAPA is not associated with this. Investigations comparing efficacy and adverse effects of PA with those of new antiarrhythmic agents available for clinical trials are indicated in the future.


Jun 1, 1975·Clinical Pharmacology and Therapeutics·M M ReidenbergH Warner
May 1, 1977·Clinical Pharmacology and Therapeutics·A J AtkinsonJ M Strong
Feb 1, 1977·Circulation· Giardina E-GVJ T Bigger
Jul 1, 1977·Clinical Pharmacology and Therapeutics·D E DrayerM M Reidenberg
Apr 1, 1975·Clinical Pharmacology and Therapeutics·C GraffnerJ Sjögren
Aug 11, 1975·Journal of Pharmacokinetics and Biopharmaceutics·J M StrongA J Atkinson
Mar 11, 1976·Clinical Pharmacology and Therapeutics·E G GiardinaE C Schreiber
Jun 1, 1973·Circulation·B D KosowskyR F Ritchie
Dec 1, 1973·European Journal of Clinical Pharmacology·E Karlsson
Dec 4, 1969·The New England Journal of Medicine·J Koch-WeserR W DeSanctis
Dec 1, 1966·American Heart Journal·B L London, I Pincus
Nov 1, 1980·The American Journal of Cardiology·E G GiardinaF I Marcus
Jan 1, 1981·The American Journal of Cardiology·R A WinkleF Peters
Dec 1, 1981·The American Journal of Cardiology·J KlugerD E Drayer
Jul 1, 1981·The American Journal of Cardiology·M SamiR F DeBusk
Sep 1, 1980·The American Journal of Cardiology·A M GreenspanM E Josephson
Aug 27, 1981·The New England Journal of Medicine·J L AndersonB Pitt
Jan 1, 1957·Circulation·B B BRODIEJ M STEELE
Feb 1, 1959·The American Journal of the Medical Sciences·S BELLETR LARA
Dec 27, 1962·The New England Journal of Medicine·A T LADD
Jul 1, 1951·Circulation·H J KAYDENB B BRODIE

❮ Previous
Next ❯

Related Concepts

Related Feeds


Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Related Papers

Annual Review of Pharmacology
E B Brown
Digestive Diseases and Sciences
A KumarF Marsh
Annals of the New York Academy of Sciences
J W Mason, L M Hondeghem
© 2021 Meta ULC. All rights reserved